N,N-dimethyl-6-propan-2-ylpyridin-2-amine

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N,N-dimethyl-6-propan-2-ylpyridin-2-amine
• 化学式: C₁₀H₁₆N₂
• 分子量: 164.25
• InChiKey: FYTGKYXFZCYSCO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  16.1
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS
  申请人：GLAXOSMITHKLINE LLC

  公开号：US20150152108A1

  公开（公告）日：2015-06-04

  The present invention relates to novel substituted bridged urea compounds, corresponding related analogs, pharmaceutical compositions and methods of use thereof. Sirtuin-modulating compounds of the present invention may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. The present invention also related to compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

  本发明涉及新型取代桥式脲化合物，相应的相关类似物，药物组合物以及其使用方法。本发明的抑制素调节化合物可用于延长细胞寿命，并治疗和/或预防各种疾病和疾病，包括但不限于与衰老或压力、糖尿病、肥胖、神经退行性疾病、心血管疾病、血液凝块疾病、炎症、癌症和/或潮红有关的疾病或疾病，以及那些会受益于增加线粒体活性的疾病或疾病。本发明还涉及包含抑制素调节化合物与另一治疗剂组合的组合物。
• SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS
  申请人：GlaxoSmithKline, LLC

  公开号：US20140288052A1

  公开（公告）日：2014-09-25

  Provided herein are novel substituted bicyclic aza-heterocycle sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

  本文提供了新型取代的双环氮杂杂环类sirtuin调节化合物及其使用方法。这些sirtuin调节化合物可用于延长细胞寿命，并治疗和/或预防各种疾病和障碍，包括与衰老或压力有关的疾病或障碍、糖尿病、肥胖症、神经退行性疾病、心血管疾病、血液凝块障碍、炎症、癌症和/或潮红，以及需要增强线粒体活性的疾病或障碍。还提供了包含sirtuin调节化合物与另一种治疗剂组合的组合物。
• Substituted Bicyclic Aza-Heterocycles and Analogues as Sirtuin Modulators
  申请人：GlaxoSmithKline, LLC

  公开号：US20140249147A1

  公开（公告）日：2014-09-04

  Provided herein are novel substituted bicyclic aza-heterocycle sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided, are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

  本文提供了一种新型的取代双环氮杂杂环类Sirtuin调节化合物及其使用方法。这些Sirtuin调节化合物可用于增加细胞寿命，治疗和/或预防各种疾病和疾病，包括与衰老或压力有关的疾病或疾病、糖尿病、肥胖症、神经退行性疾病、心血管疾病、血液凝块性疾病、炎症、癌症和/或潮红，以及需要增加线粒体活性的疾病或疾病。同时，还提供了包含Sirtuin调节化合物和另一种治疗剂的组合物。
• Nucleoside triphosphate transporter and uses thereof
  申请人：THE SCRIPPS RESEARCH INSTITUTE

  公开号：US10696719B2

  公开（公告）日：2020-06-30

  Disclosed herein are proteins, methods, cells, engineered microorganisms, and kits for generating a modified nucleoside triphosphate transporter from Phaeodactylum tricornutum. Also disclosed herein proteins, methods, cells, engineered microorganisms, and kits for production of a nucleic acid molecule that comprises an unnatural nucleotide utilizing a modified nucleoside triphosphate transporter from Phaeodactylum tricornutum.

  本文公开了蛋白质、方法、细胞、工程微生物和试剂盒，用于从三疣藻中产生修饰的核苷三磷酸转运体。本文还公开了利用来自 Phaeodactylum tricornutum 的改良三磷酸核苷转运体生产包含非天然核苷酸的核酸分子的蛋白质、方法、细胞、工程微生物和试剂盒。
• Apoptosis signal-regulating kinase 1 (ASK 1) inhibitor compounds
  申请人：PHARMAKEA, INC.

  公开号：US11345676B2

  公开（公告）日：2022-05-31

  Described herein are ASK1 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with ASK1 activity.

  本文描述了 ASK1 抑制剂、制造此类化合物的方法、包含此类化合物的药物组合物和药物，以及使用此类化合物治疗与 ASK1 活性相关的病症、疾病或失调的方法。